Clinical Trial Update: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating MAGE-A1-specific T cell receptor-transduced autologous T-cells with atezolizumab for metastatic triple-negative breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Small Cell Lung Cancer
• Triple-negative Breast Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• MAGE-A1-specific T cell receptor-transduced autologous T-cells (MAGE-A1-specific TCR-transduced autologous T cells)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-08-03